Author

Natasa Smrekar 1

1 University Medical Centre Ljubljana,Ljubljana,Slovenia;;

BIOPSIES FROM ULCER EDGE YIELD HIGHER HISTOLOGICAL ACTIVITY SCORES THAN BIOPSIES NEXT TO ULCER IN ACTIVE ULCERATIVE COLITIS

Gregor Novak, Nejc Sever, Jurij Hanzel, Matic Koželj, Tina Kurent, Natasa Smrekar, Borut Stabuc, David Drobne, Nina Zidar

INDUCTION AND EARLY MAINTENANCE VEDOLIZUMAB TROUGH LEVELS PREDICT MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE

Jurij Hanzel, Nejc Sever, Griet Compernolle, Sophie Tops, Ivan Ferkolj, Borut Stabuc, Natasa Smrekar, Matic Koželj, Tina Kurent, Gregor Novak, Ann Gils, David Drobne

INFLIXIMAB TROUGH LEVELS ABOVE 7 ΜG/ML IN INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB: BETTER CONTROL OF INFLAMMATION WITHOUT INCREASED RISK OF INFECTION    

David Drobne, Tina Kurent, Sasa Golob, Polona Svegl, Polona Rajar, Sara Terzic, Matic Koželj, Gregor Novak, Natasa Smrekar, Samo Plut, Alojz Smid, Nejc Sever, Luka Strniša, Jernej Brecelj, Darja Urlep, Josko Osredkar, Matjaz Homan, Rok Orel, Borut Stabuc, Ivan Ferkolj

Peak ustekinumab concentration after intravenous loading dose predicts faecal calprotectin normalisation in Crohn's disease: potential role for therapeutic drug monitoring?

David Drobne, Jurij Zdovc, Tina Kurent, Jurij Hanzel, Nejc Sever, Katarina Javornik, Katja Tuta, Matic Koželj, Natasa Smrekar, Gregor Novak, Ivan Ferkolj, Borut Stabuc, Tomaz Vovk, Iztok Grabnar

SHORT TERM AZATHIOPRINE CO-TREATMENT DOES NOT IMPACT LONG TERM CLINICAL OUTCOME IN INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB, BUT HAS INFLIXIMAB-SPARING EFFECT

David Drobne, Tina Kurent, Sasa Golob, Polona Svegl, Polona Rajar, Jurij Hanzel, Matic Koželj, Gregor Novak, Natasa Smrekar, Ivan Ferkolj, Borut Stabuc

Item 1 - 5 / 5
1